
### [NCIT:C7489](http://purl.obolibrary.org/obo/NCIT_C7489)
**Label:** Anal Canal Carcinoma

**Subclasses:** [NCIT:C96550](http://purl.obolibrary.org/obo/NCIT_C96550) (Anal Canal Large Cell Neuroendocrine Carcinoma), [NCIT:C96551](http://purl.obolibrary.org/obo/NCIT_C96551) (Anal Canal Small Cell Neuroendocrine Carcinoma), [NCIT:C7469](http://purl.obolibrary.org/obo/NCIT_C7469) (Anal Canal Squamous Cell Carcinoma), [NCIT:C133787](http://purl.obolibrary.org/obo/NCIT_C133787) (Anal Canal Cancer by AJCC v6 and v7 Stage), [NCIT:C96553](http://purl.obolibrary.org/obo/NCIT_C96553) (Anal Canal Mixed Adenoneuroendocrine Carcinoma), [NCIT:C7776](http://purl.obolibrary.org/obo/NCIT_C7776) (Stage III Anal Canal Cancer AJCC v6 and v7), [NCIT:C5612](http://purl.obolibrary.org/obo/NCIT_C5612) (Metastatic Anal Canal Carcinoma), [NCIT:C7794](http://purl.obolibrary.org/obo/NCIT_C7794) (Stage 0 Anal Canal Cancer AJCC v6 and v7), [NCIT:C7775](http://purl.obolibrary.org/obo/NCIT_C7775) (Stage II Anal Canal Cancer AJCC v6 and v7), [NCIT:C9037](http://purl.obolibrary.org/obo/NCIT_C9037) (Stage I Anal Canal Cancer AJCC v6 and v7), [NCIT:C6873](http://purl.obolibrary.org/obo/NCIT_C6873) (Stage IV Anal Canal Cancer AJCC v6 and v7), [NCIT:C7477](http://purl.obolibrary.org/obo/NCIT_C7477) (Paget Disease of the Anal Canal), [NCIT:C7471](http://purl.obolibrary.org/obo/NCIT_C7471) (Anal Canal Adenocarcinoma), [NCIT:C7793](http://purl.obolibrary.org/obo/NCIT_C7793) (Recurrent Anal Canal Carcinoma), [NCIT:C96549](http://purl.obolibrary.org/obo/NCIT_C96549) (Anal Canal Neuroendocrine Carcinoma), [NCIT:C5606](http://purl.obolibrary.org/obo/NCIT_C5606) (Anal Mucinous Adenocarcinoma), [NCIT:C96529](http://purl.obolibrary.org/obo/NCIT_C96529) (Anal Canal Undifferentiated Carcinoma), 

**Class expressions from DL-Learner:**

- [NCIT:C40557](http://purl.obolibrary.org/obo/NCIT_C40557) (Metastatic Lesion) 54.17%
- [NCIT:C36141](http://purl.obolibrary.org/obo/NCIT_C36141) (Intermediate Grade Lesion) 54.17%
- [NCIT:C36133](http://purl.obolibrary.org/obo/NCIT_C36133) (Well Differentiated Lesion) 54.17%
- [NCIT:C36132](http://purl.obolibrary.org/obo/NCIT_C36132) (Poorly Differentiated Lesion) 54.17%
- [NCIT:C36130](http://purl.obolibrary.org/obo/NCIT_C36130) (Low Grade Lesion) 54.17%
- Thing 52.82%
- [NCIT:C36298](http://purl.obolibrary.org/obo/NCIT_C36298) (Lesion by Grade) and (not ([NCIT:C36140](http://purl.obolibrary.org/obo/NCIT_C36140) (Grade 4 Lesion))) 49.16%
- [NCIT:C36298](http://purl.obolibrary.org/obo/NCIT_C36298) (Lesion by Grade) and (not ([NCIT:C36129](http://purl.obolibrary.org/obo/NCIT_C36129) (High Grade Lesion))) 49.16%
- [NCIT:C36298](http://purl.obolibrary.org/obo/NCIT_C36298) (Lesion by Grade) 43.69%
- [NCIT:C36298](http://purl.obolibrary.org/obo/NCIT_C36298) (Lesion by Grade) and (not ([NCIT:C38184](http://purl.obolibrary.org/obo/NCIT_C38184) (ALK Gene))) 43.69%
- [NCIT:C36298](http://purl.obolibrary.org/obo/NCIT_C36298) (Lesion by Grade) and (not ([NCIT:C38176](http://purl.obolibrary.org/obo/NCIT_C38176) (BCL2 Gene Translocation))) 43.69%
- [NCIT:C36298](http://purl.obolibrary.org/obo/NCIT_C36298) (Lesion by Grade) and (not ([NCIT:C38175](http://purl.obolibrary.org/obo/NCIT_C38175) (CD44 Messenger RNA Overexpression))) 43.69%
- [NCIT:C36298](http://purl.obolibrary.org/obo/NCIT_C36298) (Lesion by Grade) and (not ([NCIT:C38174](http://purl.obolibrary.org/obo/NCIT_C38174) (IRF4/MUM1 Messenger RNA Overexpression))) 43.69%
- [NCIT:C36298](http://purl.obolibrary.org/obo/NCIT_C36298) (Lesion by Grade) and (not ([NCIT:C38173](http://purl.obolibrary.org/obo/NCIT_C38173) (BCL2 Gene mRNA Overexpression))) 43.69%
- [NCIT:C36298](http://purl.obolibrary.org/obo/NCIT_C36298) (Lesion by Grade) and (not ([NCIT:C38172](http://purl.obolibrary.org/obo/NCIT_C38172) (Cyclin D2 Messenger RNA Overexpression))) 43.69%


